Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665976 | 1.00 | TYMP (0.37) | TYMPKDM4EHPGDTAS1R3TAS1R1 | |
| SCHEMBL1666138 | 0.94 | TYMP (0.37) | TYMPKDM4EHPGDTAS1R3TAS1R1 | |
| SCHEMBL1935584 | 0.94 | TYMP (0.37) | TYMPKDM4EHPGDTAS1R3TAS1R1 | |
| SCHEMBL31196681 | 0.89 | KDM4E (0.36) | TYMPKDM4E | |
| SCHEMBL14840190 | 0.88 | KDM4E (0.36) | TYMPKDM4E | |
| SCHEMBL1665982 | 0.86 | TYMP (0.34) | TYMP | |
| SCHEMBL1667985 | 0.86 | TYMP (0.34) | TYMP | |
| SCHEMBL23827212 | 0.86 | KDM4E (0.35) | TYMPKDM4E | |
| SCHEMBL210338 | 0.85 | KDM4E (0.36) | TYMPKDM4E | |
| SCHEMBL210035 | 0.85 | KDM4E (0.36) | TYMPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314594-B1 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8022193-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2332951-A2 | 6-modified bicyclic nucleic acid analogs | ISIS Pharmaceuticals, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2314594-A1 | 6-modified bicyclic nucleic acid analogs | Isis Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1984381-B1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100216979-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741457-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7399845-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | FOUNDATION MEDICINE, INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | TYMP 93/4885KDM4E 1867/4885HPGD 3862/4885 |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | TYMP 93/4885KDM4E 1867/4885HPGD 3862/4885 |
| US-20100216979-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | TYMP 93/4885KDM4E 1867/4885HPGD 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.